Endothelial Reprogramming to Hematopoietic Progenitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating hematopoietic multi-lineage progenitor cells (HMLPs) face challenges in achieving efficient direct conversion from somatic cells, particularly in producing functional engraftable multi-lineage hematopoietic stem and progenitor cells, due to limited understanding of molecular programs and microenvironmental cues required for their development.
Innovation Solution
The method involves culturing endothelial cells expressing specific transcription factors (FOSB, GFI1, RUNX1, and SPI1) in serum-free media with endothelial feeder cells to generate HMLPs capable of producing erythroid, lymphoid, myeloid, and megakaryocyte cells, which can engraft in mice, thereby addressing the limitations of existing techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If direct conversion from somatic cells to HMLPs is attempted, then the need for complex differentiation protocols is reduced, but the efficiency and functionality of generated HMLPs remains insufficient
Solution Approach 1:
The patent changes the parameters of the culture system by using serum-free media with defined composition and adding specific growth factors (SCF, TPO, FLT3L, IL-3, IL-6) to optimize the conversion efficiency from endothelial cells to HMLPs, thereby resolving the contradiction between protocol simplicity and generation efficiency
Solution Approach 2:
The patent introduces endothelial feeder cells as an intermediary component that provides microenvironmental cues and secreted factors to enhance the direct conversion process, improving HMLP generation efficiency while maintaining the simplicity of the direct conversion approach
2Quantity of substance
If ex-vivo expansion of HSPCs is used, then sufficient numbers of cells can be obtained, but donor availability is limited and purification methods are complicated
Solution Approach 1:
Instead of expanding existing HSPCs from donors (traditional approach), the patent inverts the approach by directly converting readily available endothelial cells into HMLPs, thereby obtaining sufficient cell numbers while eliminating the need for complex donor matching and purification procedures
Solution Approach 2:
The patent makes the conversion protocol universally applicable to various endothelial cell sources without requiring specific donor characteristics or complex purification steps, allowing autologous conversion from patient's own endothelial cells or allogeneic conversion from universal donors
3Productivity
If directed differentiation of pluripotent cells into HSPCs is attempted, then HSPCs can be generated, but the understanding of hematopoietic development is insufficient and sufficient quantities are not achieved
Solution Approach 1:
The patent changes the starting cell type parameter from pluripotent cells to endothelial cells, which are closer to the actual developmental origin of HSCs in the AGM region, thereby achieving sufficient quantities of functional HMLPs without requiring complete understanding of all molecular programs
Solution Approach 2:
The patent performs preliminary action by selecting endothelial cells as the starting material, which already possess hemogenic potential and are positioned closer to the HSC lineage in the differentiation hierarchy, thereby reducing the complexity of the differentiation process and improving output quantity
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The invention is directed to generation of hematopoietic multi-lineage progenitors (HMLPs) from endothelial cells (ECs) by effecting forced expression of certain transcription factors in the ECs and culturing the ECs in serum free media in the presence of endothelial feeder cells. The HMLPs generated in accordance with this invention can produce erythroid, lymphoid, myeloid, and megakaryocyte cells. These generated HMLPs can be used in therapeutic treatment of disorders including hematopoietic conditions.